Mechanisms of Vascular Disease in Hypertension with Special Reference to Diabetes

John S. Yudkin

doi:10.1055/s-2002-32037

Seminars in Vascular Medicine, Inhaltsverzeichnis

Semin Vasc Med 2002; 2(2): 139-148
DOI: 10.1055/s-2002-32037

Mechanisms of Vascular Disease in Hypertension with Special Reference to Diabetes

John S. Yudkin

Diabetes and Cardiovascular Disease Academic Unit, Royal Free and University College Medical School, London, England.

Abstract

ABSTRACT

In this article, it is proposed that the epidemiological observations regarding the measures of blood pressure and cardiovascular risk suggest that the vascular damage of hypertension is powerfully related to vessel stiffness. Several phenotypes within the hypertensive population, including salt sensitivity, central obesity, insulin resistance, and nonmodulating hypertension, cluster with vascular risk, and the features of the high-risk phenotype suggest a common antecedent characterizing the patient with the elevated cardiovascular risk associated with high blood pressure. The article also explores the relationship between blood pressure lowering and outcome, concluding that it is not yet fully understood how elevation of blood pressure increases risk or how reducing it produces benefit.

KEYWORDS

Hypertension - pulse pressure - vessel stiffness - diabetes - insulin resistance

Volltext

Referenzen

REFERENCES

1 Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med . 1986; 15 254-273
2 MacMahon S, Peto R, Cutler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet . 1990; 335 765-774
3 Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. Lancet . 2000; 355 175-180
4 Staessen J A, Gasowski J, Wang J G. Risks of untreated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet . 2000; 355 865-872
5 Madhavan S, Ooi W L, Cohen H, Alderman M H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension . 1994; 23 395-401
6 Mitchell G F, Moyé L A, Braunwald E, for the SAVE Investigators. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation . 1997; 96 4254-4260
7 Benetos A, Safar M, Rudnichi A. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension . 1997; 30 1410-1415
8 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension . 1998; 32 983-988
9 Franklin S S, Khan S A, Wong N D, Larson M G, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease?. <~>The Framingham Heart Study. Circulation . 1999; 100 354-360
10 Franklin S S, Gustin W, Wong N D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation . 1997; 96 308-315
11 Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. Circulation . 1989; 80 1652-1659
12 Westerhof N, O'Rourke M F. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J Hypertens . 1995; 13 943-952
13 Segers P, Stergiopulos N, Westerhof N. Quantification of the contribution of cardiac and arterial remodeling to hypertension. Hypertension . 2000; 36 760-765
14 Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Järvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes . 1999; 48 821-827
15 Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension . 1999; 33 1118-1122
16 Ruige J B, Assendelft W J, Dekker J M, Kostense P J, Heine R J, Bouter L M. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation . 1998; 97 996-1001
17 Barrett-Connor E, Khaw K-T. Is hypertension more benign when associated with obesity?. Circulation . 1985; 72(1) 53-60
18 Ferrannini E. The haemodynamics of obesity: a theoretical analysis. J Hypertens . 1992; 10 1417-1423
19 Yudkin J S, Chaturvedi N. Developing risk stratification charts for non-diabetic and diabetic subjects. Diabetic Med . 1999; 16 219-227
20 Alderman M H, Madhavan S, Ooi W L, Cohen H, Sealey J E, Laragh J H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med . 1991; 324 1098-1104
21 Williams G H, Hollenberg N K. Non-modulating hypertension. A subset of sodium-sensitive hypertension. Hypertension . 1991; I81-I85 (I81-I85)
22 White W B. How well does ambulatory blood pressure predict target-organ disease and clinical outcome in patients with hypertension?. Blood Press Monit . 1999; S17-S21 (S17-S21)
23 Morimoto A, Uzu T, Fujii T. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet . 1997; 350 1734-1737
24 Koren M J, Devereux R B, Casale P N, Savage D D, Laragh J H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med . 1991; 114 345-352
25 Rosa T T, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens . 2000; 18 645-654
26 Morgan D B, Stewart A D, Davidson C. Relations between erythrocyte lithium efflux, blood pressure and family histories of hypertension and cardiovascular disease: studies in a factory workforce and hypertension clinic. J Hypertens . 1986; 4 609-615
27 Ferri C, Bellini C, Desideri G. Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk. Diabetes . 1999; 58 1623-1630
28 Williams G H, Hollenberg N K. Non-modulating essential hypertension: a subset particularly responsive to converting enzyme inhibitors. J Hypertens Suppl . 1985; 3 S81-S87
29 Nosadini R, Cipollina M R, Solini A. Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus. J Am Soc Nephrol . 1992; 3(suppl) S56-S63
30 Ferrannini E, Buzzigoli G, Bonadonna R. Insulin resistance in essential hypertension. N Engl J Med . 1987; 317 350-357
31 Yudkin J S. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med . 1996; 28 433-438
32 Pinkney J, Stehouwer C DA, Coppack S W, Yudkin J S. Endothelial dysfunction: cause of the insulin resistance syndrome?. Diabetes . 1997; S9-S13 (S9-S13)
33 Yudkin J S, Stehouwer C DA, Emeis J J, Coppack S W. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol . 1999; 19 972-978
34 Yudkin J S, Kumari M, Humphries S, Mohamed-Ali V, for the University College London Interleukin-6 Group. Interleukin-6: a proinflammatory cytokine linking inflammation, obesity, stress, ethnicity, and coronary heart disease?. Atherosclerosis . 2000; 148 209-214
35 Serné E H, Stehouwer C DA, ter Maaten C J. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation . 1999; 99 896-902
36 Serné E H, Stehouwer C DA, ter Maaten C J, ter Wee M P, Donker A JM, Gans R OB. Birth weight relates to blood pressure and microvascular function in normal subjects. J Hypertens . 2000; 18 1421-1427
37 Hotamisligil G S, Spiegelman B M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes . 1994; 43 1271-1278
38 Steppan C M, Bailey S T, Bhat S. The hormone resistin links obesity to diabetes. Nature . 2001; 409 307-312
39 Mohamed-Ali V, Goodrick S, Rawesh A. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endo Metab . 1997; 82 4196-4200
40 Tsigos C, Kyrou I, Chala E. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism . 1999; 48 1332-1335
41 Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med . 1992; 152 1225-1229
42 Sampson M J, Griffith V S, Drury P L. Blood pressure, diet and the progression of nephropathy in patients with type 1 diabetes and hypertension. Diabet Med . 1994; 11 150-154
43 Powers D R, Wallin J D. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med . 1998; 158 793-800
44 Sacco R L, Boden-Albala B, Gan R. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol . 1998; 147 259-268
45 Reaven G M. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes . 1988; 37 1595-1607
46 Tuck M, Corry D, Trujillo A. Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am J Med . 1990; 88 210-216
47 Nielsen F S, Ali S, Rossing P. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. Diabet Med . 1997; 14 538-546
48 Toutouzas K, Stefanadis C, Tsiamis E. Aortic pressure-diameter relation in patients with non-insulin dependent diabetes mellitus: new insights. Diabetologia . 2000; 43 1070-1075
49 U.K. Prospective Diabetes Study Group (personal communication). Data presented at the UKPDS Study Group In: press
50 Stamler J, Vaccaro O, Neaton J D, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care . 1993; 16 434-444
51 Collins R, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet . 1990; 335 827-838
52 Hebert P R, Moser M, Mayer J, Glynn R J, Hennekens C H. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med . 1993; 153 578-581
53 MacMahon S, Neal B. Differences between blood-pressure-lowering drugs. Lancet . 2000; 356 352-353
54 Hansson L, Hedner T, Lund-Johansen P, for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet . 2000; 356 359-365
55 Brown M J, Palmer C R, Castaigne A. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet . 2000; 356 366-372
56 Adler A I, Stratton I M, Neil H AW, for the U.K. Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ . 2000; 321 412-419
57 Curb J D, Pressel S L, Cutler J A. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA . 1996; 276 1886-1892
58 Tuomilehto J, Rastenyte D, Birkenhager W H. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med . 1999; 340 677-684
59 Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet . 2000; 355 253-259
60 Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med . 2000; 342 145-153
61 Hansson L, Zanchetti A, Carruthers S G. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet . 1998; 351 1755-1762